NCT04167332Not yet recruiting
Prospective Collection of Samples for Urothelial Cancer of Bladder
Source: ClinicalTrials.gov · Last updated 18 Nov 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
ProCSUCaB (Prospective Collection of Samples for Urothelial Cancer of Bladder) is a monocentric, non-interventional, prospective registry that will recruit newly diagnosed intermediate- and high-risk NMIBC patients in a tertiary center in Flanders.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 630 (estimated)
- First submitted
- 15 Nov 2019
- Start date
- Dec 2019
- Primary completion date
- Dec 2024
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Diseases
- Bladder cancer
- NCT number
- NCT04167332
What you commit to
- Study type: Observational
- Planned participants: 630
- From Dec 2019 to the primary completion date, Dec 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Aged less than 18 years
Other
- Not giving or withdrawing informed consent
- Tumor histopathological type other than TCC, such as adenocarcinoma, squamous cell carcinoma
Who the study is looking for
- A signal of clinical diagnosis of bladder cancer (symptoms and/or imaging)
- Giving informed consent to collect clinical data and biological materials prior to surgery
- An approved pathological diagnosis of transitional cell carcinoma (TCC), with allowance of any variant histopathological subtype
- An approved pathological diagnosis of non-muscle-invasive bladder cancer (NMIBC), with stages of carcinoma in situ (CIS), Ta (mucosa-confined) and T1 (submucosa infiltrating)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.